Kensington, CA, United States of America

David C Myles

This inventor holds 26 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Anti-Cancer Compounds. Top assignees: Kosan Biosciences Incorporated, Olema Pharmaceuticals, Inc., University of Pennsylvania. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David C Myles. Retrieved from https://idiyas.com/inventor/david-c-myles

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 16)

% Patents Active = 84.6

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 4 (Patent Applications = 15)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 180(Granted Patents)

Location History:

Kensington, CA (US) (2003 - 2011)
Berkeley, CA (US) (2011 - 2023)

Company Filing History:

14 out of 110

Kosan Biosciences Incorporated

patents

8 out of 8

Olema Pharmaceuticals, Inc.

patents

2 out of 2,659

University of Pennsylvania

patents

4. 1 out of 19

Aurigene Oncology Limited

patents

5. 1 out of 3,742

Bristol-Myers Squibb Compnay

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Acylsulfonamide

KAT6A Inhibitors

Estrogen Receptor Antagonists

Tetrahydro-1H-pyrido

Benzopyran Compounds

Discodermolide Analogues

Ketolide Compounds

Macrolide Agents

Benzoquinone Ansamycins

Amido Macrolides

Synthetic Techniques

Guanidinobenzamides

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428379 - Acylsulfonamide KAT6A inhibitors (2025-09-30),

2. 12370181 - Regimens of estrogen receptor antagonists (2025-07-29),

3. 11672785 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2023-06-13),

4. 11229630 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2022-01-25),

5. 10624878 - Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs (2020-04-21),

6. 10292971 - Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs (2019-05-21),

7. 9018244 - Benzopyran compounds, compositions and uses thereof (2015-04-28),

8. 8193241 - Discodermolide analogues and methods of their use (2012-06-05),

9. 8063249 - Substituted triphenyl butenes (2011-11-22),

10. 8063021 - Ketolide anti-infective compounds (2011-11-22),

11. 7655808 - Leptomycin compounds (2010-02-02),

12. 7582611 - Motilide compounds (2009-09-01),

13. 7446196 - Leptomycin compounds (2008-11-04),

14. 7405208 - Benzoquinone ansamycins (2008-07-29),

15. 7348436 - Compounds useful for the synthesis of (+)-discodermolide and methods thereof (2008-03-25),

Title: The Innovative Journey of David C Myles

Introduction: David C Myles, a distinguished inventor hailing from Kensington, CA (US), has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: David C Myles holds several patents in the field of renewable energy technologies, including a recent patent for a solar panel efficiency optimization system.

Career Highlights: With a career spanning over two decades, David C Myles has worked for various tech companies, leading research and development teams focused on sustainability and clean energy solutions. His work has been pivotal in advancing the renewable energy sector.

Collaborations: Throughout his career, David C Myles has collaborated with top researchers, engineers, and scientists in the industry to bring cutting-edge technologies to life. His collaborative spirit has led to the successful development of several groundbreaking inventions.

Conclusion: David C Myles continues to be a driving force in the field of renewable energy innovation, with a passion for creating sustainable solutions that benefit both the environment and society as a whole.

Profile summary based on public USPTO records.